Full metadata record

DC Field Value Language
dc.contributor.authorAbdel-Maksoud, Mohammed S.-
dc.contributor.authorEl-Gamal, Mohammed I.-
dc.contributor.authorBenhalilou, Dalia Reyane-
dc.contributor.authorAshraf, Sandy-
dc.contributor.authorMohammed, Shatha Abdulghaffar-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-19T20:33:42Z-
dc.date.available2024-01-19T20:33:42Z-
dc.date.created2021-09-02-
dc.date.issued2019-03-
dc.identifier.issn0198-6325-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/120307-
dc.description.abstractThe mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.-
dc.languageEnglish-
dc.publisherWILEY-
dc.subjectORALLY BIOAVAILABLE INHIBITORS-
dc.subjectLIFE-SPAN EXTENSION-
dc.subjectMAMMALIAN TARGET-
dc.subjectBIOLOGICAL EVALUATION-
dc.subjectAMINO-ACID-
dc.subjectIN-VITRO-
dc.subjectPYRIMIDINE-DERIVATIVES-
dc.subjectANTITUMOR-ACTIVITY-
dc.subjectSIGNALING PATHWAY-
dc.subjectKINASE INHIBITOR-
dc.titleMechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors-
dc.typeArticle-
dc.identifier.doi10.1002/med.21535-
dc.description.journalClass1-
dc.identifier.bibliographicCitationMEDICINAL RESEARCH REVIEWS, v.39, no.2, pp.631 - 664-
dc.citation.titleMEDICINAL RESEARCH REVIEWS-
dc.citation.volume39-
dc.citation.number2-
dc.citation.startPage631-
dc.citation.endPage664-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000458338000007-
dc.identifier.scopusid2-s2.0-85054011986-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeReview-
dc.subject.keywordPlusORALLY BIOAVAILABLE INHIBITORS-
dc.subject.keywordPlusLIFE-SPAN EXTENSION-
dc.subject.keywordPlusMAMMALIAN TARGET-
dc.subject.keywordPlusBIOLOGICAL EVALUATION-
dc.subject.keywordPlusAMINO-ACID-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusPYRIMIDINE-DERIVATIVES-
dc.subject.keywordPlusANTITUMOR-ACTIVITY-
dc.subject.keywordPlusSIGNALING PATHWAY-
dc.subject.keywordPlusKINASE INHIBITOR-
dc.subject.keywordAuthoraging-
dc.subject.keywordAuthoranticancer-
dc.subject.keywordAuthorkinase inhibitors-
dc.subject.keywordAuthormTOR-
dc.subject.keywordAuthorPI3K-
Appears in Collections:
KIST Article > 2019
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE